Loading...

BioMarin Pharmaceutical Inc.

0HNC.L•LSE
Healthcare
Medical - Pharmaceuticals
£57.97
£-0.27(-0.46%)

BioMarin Pharmaceutical Inc. (0HNC.L) Stock Overview

Explore BioMarin Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 78.3/100

Key Financials

Market Cap11.1B
P/E Ratio16.97
EPS (TTM)$0.21
ROE0.11%
Fundamental Analysis

AI Price Forecasts

1 Week$55.87
1 Month$58.78
3 Months$61.34
1 Year Target$56.94

0HNC.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioMarin Pharmaceutical Inc. (0HNC.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 49.88, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $56.94.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 16.97 and a market capitalization of 11.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
5.05%
5-Day Change
-15.89%
1-Month Change
-22.19%
3-Month Change
-15.13%
6-Month Change
-19.33%
Year-to-Date (YTD) Change
-15.42%
1-Year Change
-36.95%
3-Year Change
-34.68%
5-Year Change
-36.53%
All-Time (Max) Change
-36.53%

Contact Information

https://www.biomarin.com
415 506 6700
770 Lindaro Street, San Rafael, CA, 94901

Company Facts

3,040 Employees
IPO DateJan 29, 2018
CountryUS
Actively Trading

Frequently Asked Questions

;